Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis

Clinical Cancer Research

Volumn 8, Issue 1, 2002, Pages 210-216

  Gillies, Stephen D ^a   Lo, Kin Ming ^a   Lan, Yan ^a   Dahl, Thomas ^a   Wong, Wai Keung ^a   Burger, Christa ^b  

^a Lexigen Pharmaceuticals   (United States)

^b MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE ANTIBODY; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; IN VITRO STUDY; IN VIVO STUDY; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR BINDING; TUMOR REGRESSION;

ANIMALS; CATHEPSINS; COLONIC NEOPLASMS; CYSTEINE ENDOPEPTIDASES; HALF-LIFE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FC FRAGMENTS; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MUTAGENESIS, SITE-DIRECTED; MUTATION; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0036155035     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors
2. A theoretical model of γ-globulin metabolism
3. The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor
4. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases
5. High level expression and secretion of Fc-X fusion proteins in mammalian cells
6. Antibodytargeted interleukin-2 stimulates T-cell killing of autologous tumor cells
7. Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies
8. Disialoganglioside GD2 on neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth
9. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins
10. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficient mice
11. T cell mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy
12. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow
13. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases
14. Improved efficacy of mouse antibody-cytokine fusion proteins in syngeneic mouse tumor models is due to their reduced immunogenicity